FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Eupraxia Pharmaceuticals Inc. Stock AnalysisComprehensive stock analysis for Eupraxia Pharmaceuticals Inc. (EPRXF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisEPRXF
EPRXF
Eupraxia Pharmaceuticals Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
EPRXF
Home🔹Stocks🔹Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Inc.

EPRXF•OTC

Eupraxia Pharmaceuticals Inc.

EPRXF•OTC
Market cap
$108.29M
Sentiment

Your view on EPRXF

Mkt Cap
$108.29M
Sentiment
Your view
EPRXF
Eupraxia Pharmaceuticals Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
EPRXF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Eupraxia Pharmaceuticals Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
James A. Helliwell FRCPC,
Headquarters
2067 Cadboro Bay Road, Victoria, BC, CA
Industry
Biotechnology
Sector
Healthcare
CEO
James A. Helliwell FRCPC,
Headquarters
2067 Cadboro Bay Road, Victoria, BC, CA
Description

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News